Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161044 · ClinicalTrials.gov registry record · NA
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
A NA study of Chronic Schizophrenia, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00161044 is a NA study of Chronic Schizophrenia that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00161044, a NA study of Chronic Schizophrenia, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.
Conditions Studied
Interventions
- DRUG Galantamine
Study Locations (1)
Maryland
- Maryland Psychiatric Research Center - Catonsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00161044
The ClinicalTrials.gov registry entry for NCT00161044 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Galantamine is the first listed.
NCT00161044 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00161044 about?
NCT00161044 is a clinical study titled "An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms". The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.
What is the current status of trial NCT00161044?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2004-09. Estimated completion is 2005-09.
What conditions does trial NCT00161044 study?
This clinical trial studies the following conditions: Chronic Schizophrenia.
What interventions are being tested in trial NCT00161044?
The interventions under investigation include: Galantamine (DRUG).
Who is sponsoring clinical trial NCT00161044?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00161044 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.